Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Metabolomic signature of the seminal plasma in men with severe oligoasthenospermia.
Boguenet M, Bocca C, Bouet PE, Serri O, Chupin S, Tessier L, Blanchet O, El Hachem H, Chao de la Barca JM, Reynier P, May-Panloup P. Boguenet M, et al. Among authors: serri o. Andrology. 2020 Nov;8(6):1859-1866. doi: 10.1111/andr.12882. Epub 2020 Aug 31. Andrology. 2020. PMID: 32770844 Free article.
Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech).
Nicol T, Lefeuvre C, Serri O, Pivert A, Joubaud F, Dubée V, Kouatchet A, Ducancelle A, Lunel-Fabiani F, Le Guillou-Guillemette H. Nicol T, et al. Among authors: serri o. J Clin Virol. 2020 Aug;129:104511. doi: 10.1016/j.jcv.2020.104511. Epub 2020 Jun 15. J Clin Virol. 2020. PMID: 32593133 Free PMC article.
The role of diabetes in acromegaly associated neoplasia.
Cheng S, Gomez K, Serri O, Chik C, Ezzat S. Cheng S, et al. Among authors: serri o. PLoS One. 2015 May 21;10(5):e0127276. doi: 10.1371/journal.pone.0127276. eCollection 2015. PLoS One. 2015. PMID: 25996963 Free PMC article.
Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Reséndiz K, Ruffin M, Chen Y, Colao A. Sheppard M, et al. Among authors: serri o. Pituitary. 2015 Jun;18(3):395-6. doi: 10.1007/s11102-014-0628-z. Pituitary. 2015. PMID: 25566750 Free PMC article. No abstract available.
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M, Bronstein MD, Freda P, Serri O, De Marinis L, Naves L, Rozhinskaya L, Hermosillo Reséndiz K, Ruffin M, Chen Y, Colao A. Sheppard M, et al. Among authors: serri o. Pituitary. 2015 Jun;18(3):385-94. doi: 10.1007/s11102-014-0585-6. Pituitary. 2015. PMID: 25103549 Free PMC article. Clinical Trial.
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A. Petersenn S, et al. Among authors: serri o. J Clin Pharmacol. 2014 Nov;54(11):1308-17. doi: 10.1002/jcph.326. Epub 2014 May 24. J Clin Pharmacol. 2014. PMID: 24800725 Clinical Trial.
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M; Pasireotide C2305 Study Group. Colao A, et al. J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. doi: 10.1210/jc.2013-2480. Epub 2014 Jan 13. J Clin Endocrinol Metab. 2014. PMID: 24423324 Free PMC article. Clinical Trial.
91 results